Team

The ACS Biomarker team is an ambitious group of life science professionals with a strong scientific and commercial background and relevant experience in diagnostics and pharma industry. The team established an extensive international academic and private network in the field of cardiovascular biomarkers.

Heico Breek

Chief Executive Officer (CEO)

Before joining ACS Biomarker, Heico Breek held senior management positions in both Europe and the United States at Aventis Pharma as Vice-President Global Marketing for Aventis’ Arthritis and Bone Group. He was General Manager of Aventis AB in Sweden. After moving to biotech he became Chief Commercial Officer of Tigenix NV, a Belgian company active in the field of Regenerative Medicine. Heico holds a Medical Degree from the VU University Amsterdam and an executive MBA.

Yigal Pinto

Chief Scientific Officer (CSO)

Yigal Pinto was trained as a cardiologist at the University of Groningen in the Netherlands and he holds a PhD from the same university. He is also trained in molecular biology and genetics of the heart at Harvard Medical School, Boston (USA) and at the Max Delbruck Center for Molecular Medicine, Berlin (Germany). His main interest is the molecular genetics of heart failure. From 2001-2007 he was staff cardiologist at the University of Maastricht and in 2005 he was appointed as Full Professor of Cardiology. He discovered the heart failure biomarker galectin-3. In 2008 he moved to the AMC in Amsterdam to become the scientific director of the Heart Center. Yigal is an established investigator of the Netherlands Heart Foundation.

Tilman Hackeng

Chief Technology Officer (CTO)
Tilman Hackeng studied (bio)chemistry at the University of Utrecht were he obtained his Masters Degree in 1988. After his Ph.D. in 1993, he left for The Scripps Research Institute, La Jolla, CA, USA. In 1998 he was granted a position as a Research Fellow of the Royal Netherlands Academy of Arts and Sciences (KNAW) at the University Maastricht. Currently he is chairman of the Department of Biochemistry of the Universiy Maastricht and applies his research to unraveling molecular mechanisms leading to thrombosis and the design and chemical synthesis of agents for in vivo imaging of venous and arterial disease. He is board member of the Cardiovascular Research Institute Maastricht and president of the Netherlands Society on Thrombosis and Hemostasis.

Marlon Dijkshoorn

Chief Financial Officer (CFO)

Having more than 25 years of experience in financial management from large enterprises to venture funds and small technology companies, Marlon acts as part time CFO for ACS Biomarker. From 1999 to 2004 Marlon acted as CFO for Life Science Partners assisting in the establishment of Funds I and II. During 2005 Marlon established Finmar B.V. a boutique financial advisory and management service for SMEs in the health and medical sectors. Marlon provides financial planning, tax and strategic support for SMEs in the early phases. Having experience of sitting on both sides of the risk capital table Marlon provides critical support in raising risk capital investments. Marlon holds a degree in Business Economy from the Erasmus University. 

Joost Leenders

Operations Manager

Joost was trained as a molecular biologist at the University of Maastricht. After his Master's degree he worked as a scientist at the University of Melbourne in Australia. Having returned to the Netherlands Joost obtained a PhD in the field of molecular cardiology on the role of the gene KLF15 in heart failure at the University of Amsterdam. In 2012 he joined ACS Biomarker as project leader. At ACS Biomarker Joost is responsible for all miRNA R&D projects.

contact: joost.leenders@acsbiomarker.com

Bookmark and Share